GSK Takes A Header As Vaccine Sales Plummet, Miss
GSK stock plummeted due to declining vaccine sales in Q3. Sales dropped 2% to 8.01 billion pounds, missing analyst estimates. Vaccine sales, notably for Arexvy and Shingrix, fell, but GSK maintains its sales growth outlook for the year.